High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa

South African Medical Journal

Volumn 104, Issue 4, 2014, Pages 288-291

  Whitehorn, H ^a   Sibanda, M ^b   Lacerda, M ^a   Spracklen, T ^a   Ramma, L ^b   Dalvie, S ^b   Ramesar, R ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUDIOMETRY; BILATERAL HEARING LOSS; CHANG OTOTOXICITY SCALE; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HEAD AND NECK TUMOR; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEOPLASM; OTOTOXICITY; PREVALENCE; RETROSPECTIVE STUDY; SOUTH AFRICA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; AUDIOMETRY, PURE-TONE; CISPLATIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENITAL NEOPLASMS, FEMALE; HEAD AND NECK NEOPLASMS; HEARING LOSS, BILATERAL; HUMANS; INCIDENCE; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; YOUNG ADULT;

EID: 84897145450     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.7389     Document Type: Article

References (19)

1. McKeage MJ. Comparative adverse eff ect profi les of platinum drugs. Drug Saf 1995;13(4):228-244. [http://dx.doi. org/10.2165/00002018-199513040-00003]
2. Siddik ZH. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22(47):7265-7279. [http:// dx.doi.org/10.1038/sj.onc.1206933]
3. Buhrer C, Weinel P, Sauter S, Reiter A, Riehm H, Laszig R. Acute onset deafness in a 4-year old girl aft er a single infusion of cisplatinum. Pediatr Hematol Oncol 1990;7(2):145-148. [http:// dx.doi.org/10.3109/08880019009033384]
4. Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol 2007;29(6):355-360. [http://dx.doi.org/10.1097/ MPH.0b013e318059c220]
5. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may infl uence academic and social development. J Clin Oncol 2005;23(34):8588-8596. [http://dx.doi.org/10.1200/JCO.2004.00.5355]
6. Li Y, Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: Th e infl uence of age and the cumulative dose. Eur J Cancer 2004;40(16):2445-2451. [http://dx.doi.org/10.1016/j.ejca.2003.08.009]
7. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010;28(10):1788-1795. [http://dx.doi.org/10.1200/JCO.2009.24.4228]
8. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007;226(1-2):157-167. [http://dx.doi.org/10.1016/j. heares.2006.09.015]
9. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in paediatric oncology patients. Pediatr Blood Cancer 2012;59(1):144-148. [http://dx.doi.org/10.1002/pbc.24138]
10. Bokemeyer C, Berger CC, Haertmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998;77(8):1355-1362. [http:// dx.doi.org/10.1038/bjc.1998.226]
11. Eiamprapai P, Yamamoto N, Hiraumi H, et al. Eff ect of cisplatin on distortion product otoacoustic emissions in Japanese patients. Laryngoscope 2012;122(6):1392-1396. [http://dx.doi. org/10.1002/lary.23336]
12. Campbell KC, Meech RP, Klemens JJ, et al. Prevention of noise- and drug-induced hearing loss with D-methionine. Hear Res 2007;226(1-2):92-103. [http://dx.doi.org/10.1016/j. heares.2006.11.012]
13. American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA Practice Policy 1994;36:11-19. [http://dx.doi.org/10.1044/policy.GL1994-00003]
14. Piel U, Meyer D, Perlia CP, Wolfe VI. Eff ects of cisdiamminedichloroplatinum (NSC-1 19875) on hearing function in man. Cancer Chemother Rep 1974;58(6):871-875.
15. Stewart BW, Kleihues P. World Health Organization: International Agency for Research on Cancer. World Cancer Report. Lyon: IARC Press, 2003.
16. Andrade V, Khoza-Shangase K, Hajat F. Perceptions of oncologists at two state hospitals in Gauteng regarding the ototoxic eff ects of cancer chemotherapy: A pilot study. African Journal of Pharmacy and Pharmacology 2009;3(6):307-318.
17. Helson L, Okonkwo E, Anton L, Cvitkovic E. cis-Platinum ototoxicity. Clin Toxicol 1978;13(4):469-478. [http://dx.doi. org/10.3109/15563657808988252]
18. Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DY. Sensorineural hearing loss aft er radiotherapy and chemoradiotherapy: A single, blinded, randomized study. J Clin Oncol 2006;24(12):1904-1909. [http://dx.doi.org/10.1200/JCO.2005.05.0096]
19. Rednam S, Scheurer ME, Adesina A, Lau CC, Okcu MF. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma. Pediatr Blood Cancer 2013;60(4):593-598. [http://dx.doi.org/10.1002/pbc.24366]